A Randomized, Double-blind, Placebo-controlled, Single Day/Multiple Day Dosing, Phase I Clinical Trial to Investigate the Systemic Exposure, Safety and Local Tolerability of SJP002 Ophthalmic Solution in Healthy Korean Male Subjects
Latest Information Update: 15 Apr 2022
At a glance
- Drugs Rebamipide (Primary)
- Indications Dry eyes
- Focus Adverse reactions
- Sponsors Samjin Pharmaceutical Company
- 04 Apr 2022 Primary endpoint of the study changed to pharmacokinetic parameters.
- 18 Mar 2022 Status changed from recruiting to completed.
- 10 Oct 2016 New trial record